(Incorporated in Delaware)

We are a clinical biotech developing next-generation and long-acting precision bispecific therapies for autoimmune and inflammatory diseases.

Since our inception on March 14, 2024, we have acquired assets from BioNTech (Zhuhai) Pharmaceuticals R&D, a subsidiary of BioNTech then known as Biotheus (“BioNTech Zhuhai”), that became our lead product candidates, BBT001 and BBT002.

Our lead product candidate, BBT001, a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated pathways, interleukin-4 receptor alpha (“IL-4Rα”) and interleukin-31 (“IL-31”), is designed to simultaneously address core Type 2 inflammation and chronic itch, the two defining burdens of atopic dermatitis (“AD”) and other inflammatory skin diseases.

We plan to initiate study start-up activities for our Phase 2b dose-ranging clinical trial of a SubQ formulation of BBT001 to treat patients with moderate-to-severe AD (“Phase 2b AD Study”) by the end of 2026.

Our second lead product candidate, BBT002, a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated pathways, IL-4Rα and interleukin-5 (“IL-5”), is designed to simultaneously address both central pillars of Type 2 inflammation, the interleukin-4 (“IL-4”) and interleukin-13 (“IL-13”) axis and the IL-5 and eosinophil (“EOS”) axis, in a single molecule. BBT002 has also been engineered using the same HLE technology as BBT001 with the goal of enabling extended dosing intervals relative to conventional antibody therapies. We believe BBT002 has the potential to address a number of Type 2 inflammatory disorders across respiratory and allergic diseases.

We are currently evaluating BBT002 for: (i) the treatment of chronic obstructive pulmonary disease (COPD) in our global Phase 1 clinical trial in the United States, Australia, Europe, Georgia, and New Zealand (“Global BBT002 Study”); and (ii) our Phase 1/2a clinical trial for COPD in China (“China COPD Study”). We are also evaluating BBT002 for the treatment of chronic rhinosinusitis with nasal polyps (“CRSwNP”) in a Phase 2a clinical trial in China (“China CRSwNP Study”).

We are also advancing two preclinical product candidates: BBT003, a next-generation, long-acting bispecific antibody targeting Tumor Necrosis Factor-like ligand 1A (“TL1A”) and the p19 subunit of interleukin-23 (“IL-23p19”) for inflammatory bowel diseases (“IBD”), including Crohn’s disease (“CD”) and ulcerative colitis (“UC”), for which we plan to enter the clinic by the end of 2026, and BBT004, a next-generation, long-acting dual B-cell depletion bispecific antibody for autoantibody-driven AID, for which we plan to enter the clinic by the end of 2027.

Each of our programs is designed to be a “pipeline-in-a-molecule” with the potential for broad applicability across multiple indications.

Note: The company has not generated any product revenue so far.

Note: Net loss is for the 12 months that ended on June 30, 2026. 

(Note: Bambusa Therapeutics filed its S-1 on Oct. 9, 2026, for its IPO, without disclosing the terms. Estimated proceeds are $100 million.)